3 Stocks Dragging The Health Care Sector Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 77 points (-0.5%) at 16,791 as of Thursday, June 26, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,231 issues advancing vs. 1,744 declining with 167 unchanged.

The Health Care sector currently sits down 0.4% versus the S&P 500, which is down 0.4%. On the negative front, top decliners within the sector include Intercept Pharmaceuticals ( ICPT), down 4.6%, Community Health Systems ( CYH), down 3.8%, Universal Health Services ( UHS), down 3.7%, HCA Holdings ( HCA), down 2.3% and Grifols ( GRFS), down 1.6%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. Endo International ( ENDP) is one of the companies pushing the Health Care sector lower today. As of noon trading, Endo International is down $1.27 (-1.8%) to $70.35 on light volume. Thus far, 534,685 shares of Endo International exchanged hands as compared to its average daily volume of 2.8 million shares. The stock has ranged in price between $70.17-$72.10 after having opened the day at $71.51 as compared to the previous trading day's close of $71.62.

Endo International plc, a specialty healthcare company, develops, manufactures, markets, and distributes branded pharmaceutical and generic products, and medical devices worldwide. Endo International has a market cap of $10.7 billion and is part of the drugs industry. Shares are up 6.2% year-to-date as of the close of trading on Wednesday. Currently there are 8 analysts that rate Endo International a buy, 1 analyst rates it a sell, and 6 rate it a hold.

TheStreet Ratings rates Endo International as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, expanding profit margins and notable return on equity. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, weak operating cash flow and generally higher debt management risk. Get the full Endo International Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Eli Lilly and ( LLY) is down $0.39 (-0.6%) to $62.61 on average volume. Thus far, 1.9 million shares of Eli Lilly and exchanged hands as compared to its average daily volume of 4.7 million shares. The stock has ranged in price between $62.44-$62.98 after having opened the day at $62.84 as compared to the previous trading day's close of $63.00.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health Products. Eli Lilly and has a market cap of $69.3 billion and is part of the drugs industry. Shares are up 23.5% year-to-date as of the close of trading on Wednesday. Currently there are 5 analysts that rate Eli Lilly and a buy, 2 analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Eli Lilly and as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Eli Lilly and Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Bristol-Myers Squibb Company ( BMY) is down $0.43 (-0.9%) to $49.30 on average volume. Thus far, 3.9 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 8.8 million shares. The stock has ranged in price between $49.22-$49.91 after having opened the day at $49.79 as compared to the previous trading day's close of $49.73.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company has a market cap of $80.0 billion and is part of the drugs industry. Shares are down 6.4% year-to-date as of the close of trading on Wednesday. Currently there are 10 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 6 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and notable return on equity. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Bristol-Myers Squibb Company Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing